Anti-inflammatory activity of ansamycins

References

• Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI. Development potential of rifalazil. Expert Opin. Investig. Drugs12(2), 255–271 (2003).
   PubMed Web of Science ®Google Scholar
• Lenaerts AM, Chase SE, Cynamon MH. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. Antimicrob. Agents Chemother.44(11), 3167–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Shoen CM, De Stefano MS, Cynamon MH. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin. Infect. Dis.30(Suppl. 3), S288–S290 (2000).
   PubMedGoogle Scholar
• Maw WW, Tomioka H, Sato K, Saito H. Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic nude mice. Int. J. Lepr. Other Mycobact. Dis.65(3), 345–351 (1997).
   PubMedGoogle Scholar
• Dhople AM. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Antimycobacterial activity of KRM-1648. Arzneimittelforsch51(6), 501–505 (2001).
   PubMed Web of Science ®Google Scholar
• Bryskier A. Ansamycins. In: Antibiotics and Antibacterial Agents. Bryskier A (Ed.). ASM Press, Washington DC, USA (2005) (In press).
   Google Scholar
• Laroux FS. Mechanisms of inflammation: the good, the bad and the ugly. Front. Biosci.9, 3156–3162 (2004).
   PubMedGoogle Scholar
• Rankin JA. Biological mediators of acute inflammation. AACN Clin. Issues15(1), 13–17 (2004).
   Google Scholar
• Liu H, Pope RM. Phagocytes: mechanisms of inflammation and tissue destruction. Rheum. Dis. Clin. North Am.30(1), 19–39 (2004).
   PubMed Web of Science ®Google Scholar
• Sherwood ER, Toliver-Kinsky T. Mechanisms of the inflammatory response. Best Pract. Res. Clin. Anaesthesiol.18(3), 385–405 (2004).
   PubMed Web of Science ®Google Scholar
• Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or ‘immuno-fairy’ tales. Clin. Microbiol. Rev.13, 615–650 (2000).
   PubMed Web of Science ®Google Scholar
• Labro MT. Antibiotics as anti-inflammatory agents. Curr. Opinion Invest. Drugs3, 61–68 (2002).
   PubMedGoogle Scholar
• Dajani BM, Canady MS, Thompson JS, Kasik JE. Rifampicin: an immunomodulator? Lancet2(7786) 1094 (1972).
   PubMedGoogle Scholar
• Floersheim GL. Suppression of cellular immunity in vivo by rifampicin. Experientia29(12), 1545–1546 (1973).
   PubMedGoogle Scholar
• Galal SH, Khalil SH, el Husseiny W, Brock J. Cell mediated and humoral immunity and light-chain proteinuria in rifampicin-treated tuberculous patients. Allerg. Immunol. (Leipz.)34, 249–254 (1988).
   PubMedGoogle Scholar
• Grennan DM, Sturrock RD. Polyarthritis, hepatitis and antinative DNA antibodies after treatment with ethambutol and rifampicin. Tubercle57(4), 259–261 (1976).
   PubMedGoogle Scholar
• Roszkowski W, Lipinska R, Roszkowski K, Jeljaszewicz J, Pulverer G. Rifampicin-induced suppression of antitumor immunity. Med. Microbiol. Immunol.172(4), 197–205 (1984).
   PubMed Web of Science ®Google Scholar
• Bellahsene A, Forsgren A. Effect of rifampin on the immune response in mice. Infect. Immun.27(1), 15–20 (1980).
   PubMed Web of Science ®Google Scholar
• Konrad P, Stenberg P. Rifampicin quinone is an immunosuppressant, but not rifampicin itself. Clin. Immunol. Immunopathol.46(1), 162–166 (1988).
   PubMedGoogle Scholar
• Sborgia G, Lafronza V, Balestrazzi E. Clinical trial of a new antibiotic (rifampicin) in some aspecific inflammatory disease of the eye. Ann. Ottamol. Clin. Ocul.96(7), 633–640 (1969).
   Google Scholar
• Tunkel AR, Scheld WM. Corticosteroids for everyone with meningitis? N. Engl. J. Med.347(20), 1613–1615 (2002).
   PubMed Web of Science ®Google Scholar
• de Gans J, van de Beek D, for the European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N. Engl. J. Med.347(20), 1549–1556 (2002).
   PubMed Web of Science ®Google Scholar
• Dexamethasone in adults with bacterial meningitis: correspondence. N. Engl. J. Med.348, 954–957 (2003).
   PubMedGoogle Scholar
• Stuertz K, Schmidt H, Trostdorf F, Eiffert H, Mäder M, Nau R. Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with nonbacteriolytic antibiotics than with Ceftriaxone. Scand. J. Infect. Dis.31, 367–370 (1999).
   PubMed Web of Science ®Google Scholar
• Nau R, Wellmer A, Soto A et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meninigitis. J. Infect. Dis.179(6), 1557–1560 (1999).
   PubMed Web of Science ®Google Scholar
• Spreer A, Kerstan H, Bottcher T et al. Reduced release of pneumolysin in Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison with ceftriaxone. Antimicrob. Agents Chemother.47(8), 2649–6654 (2003).
   PubMed Web of Science ®Google Scholar
• Bottcher T, Gerber J, Wellmer A et al. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis.181, 2095–2098 (2000).
   PubMedGoogle Scholar
• Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob. Agents Chemother.47(4) 1313–1317 (2003).
   PubMed Web of Science ®Google Scholar
• Greenstein RJ. Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease. Lancet3(8), 507–514 (2003).
   Google Scholar
• Selby W. Pathogenesis and therapeutic aspects of Crohn’s disease. Vet. Microbiol.77(3–4), 505–511 (2000).
   PubMedGoogle Scholar
• Bull TJ, McMinn EJ, Sidi-Boumedine K et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn’s disease. Antimicrob. Agents Chemother.41(7), 2915–2923 (2003).
   Google Scholar
• Greenstein RJ, Collins MT. Emerging pathogens: is Mycobacterium avium subspecies paratuberculosis zoonotic? Lancet364, 396–397 (2004).
   PubMedGoogle Scholar
• Wirotsko E, Johnson L, Wirotsko B. Crohn’s disease. Rifampicin treatment of the ocular and gut disease. Hepatogastroenterology34, 90–93 (1987).
   PubMedGoogle Scholar
• Rutgeerts P, Geboes K, Vantrappen G et al. Rifabutin and ethambutol do not help recurrent Crohn’s disease in the neoterminal ileum. J. Clin. Gastroenterol.15, 24–28 (1992).
   PubMedGoogle Scholar
• Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am. J. Gastroenterol.89, 513–518 (1994).
   PubMed Web of Science ®Google Scholar
• Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn’s disease. Am. J. Gastroenterol.95(3), 725–729 (2000).
   PubMed Web of Science ®Google Scholar
• Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. 2-year-outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother.39, 393–400 (1997).
   PubMed Web of Science ®Google Scholar
• Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Dig. Liver Dis.34(1), 29–38 (2002).
   PubMedGoogle Scholar
• Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig. Liver Dis.34(1), 22–28 (2002).
   PubMedGoogle Scholar
• Douglass A, Cann PA, Bramble MG. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn’s disease. Gut46(Suppl. A11) (2000).
   Google Scholar
• Labro MT. Cellular and molecular effects of macrolides. Curr. Pharm. Des.10(25), 3067–3080 (2004).
   PubMedGoogle Scholar
• Gionchetti P, Rizello F, Venturi A et al. Review-antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur. Rev. Med. Pharmacol. Sci.3, 27–30 (1999).
   PubMedGoogle Scholar
• Mobley JL. Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance? Med. Hypotheses.62(5), 839–843 (2004).
   PubMed Web of Science ®Google Scholar
• Rothschild BM. Unified theory of origins of erosive arthritis: conditioning as a protective/directing mechanism? J. Rheumatol.30, 2095–2102 (2003).
   PubMed Web of Science ®Google Scholar
• Kim HA, Yoo CD, Baek HJ et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin. Exp. Rheumatol.16(1), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Evanchick CC, Davis DE, Harrington TM. Tuberculosis of peripheral joints: an often missed diagnosis. J. Rheumatol.13(1), 187–189 (1986).
   PubMed Web of Science ®Google Scholar
• Mc Conkey B, Situnayake RD. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J. Rheumatol.15, 46–50 (1988).
   PubMedGoogle Scholar
• Caruso I. Twenty years of experience with intra-articular rifamycin for chronic arthritides. J. Int. Med. Res.25, 307–317 (1997).
   Google Scholar
• Spisani S, Traniello S, Martuccio C, Rizzuti O, Cellai L. Rifamycins inhibit human neutrophil functions: new derivatives with potential anti-inflammatory activity. Inflammation21, 391–400 (1997).
   PubMedGoogle Scholar
• Spisani S, Traniello S, Onori AM, Rizzuti O, Martuccio C, Cellai L. 3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions. Inflammation22(5), 459–469 (1998).
   PubMedGoogle Scholar
• Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J. Chemother.16(4), 357–361 (2004).
   PubMed Web of Science ®Google Scholar
• Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-α production. Intern. Immunopharmacol.3, 513–522 (2003).
   PubMed Web of Science ®Google Scholar
• Ibrahim MS, Maged ZA, Huron A, Khalil RY, Attallah AM. Antibiotics and immunity: effects of antibiotics on natural killer, antibody-dependent cell-mediated cytotoxicity and antibody production. Chemioterapia6(6), 426–430 1987.
   PubMedGoogle Scholar
• Sacha PT, Zaremba ML, Jakoniuk P. The effect of selected antibacterial antibiotics on production of interferon gamma by mouse T-lymphocytes stimulated by Listeria monocytogenes.Med. Dosw. Mikrobiol.51, 413–419 (1999).
   PubMedGoogle Scholar
• Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Med.4(1), 92–96 (1998).
   PubMed Web of Science ®Google Scholar
• Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM. Potential of rifamides to inhibit TNF-induced NF-κB activation. J. Antimicrob. Chemother.49(3), 531–534 (2002).
   PubMed Web of Science ®Google Scholar
• Yerramasetti R, Gollapudi S, Gupta S. Rifampicin inhibits CD95-mediated apoptosis of Jurkat T-cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J. Clin. Immunol.22, 37–47 (2002).
   PubMedGoogle Scholar
• Gollapudi S, Jaidka S, Gupta S. Molecular basis of rifampicin-induced inhibition of anti CD95-induced apoptosis of peripheral blood T-lymphocytes: the role of CD95 ligand and FLIPs. J. Clin. Immunol.23, 11–22 (2003).
   PubMed Web of Science ®Google Scholar
• Giuliani A, Porcelli SA, Tentori L et al. Effect of rifampicin on CD1b expression and double-negative T-cell responses against mycobacteria-derived glycolipid antigen. Life Sci.63(12), 985–994 (1998).
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G, Porcelli SA et al. Rifampicin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrob. Agents Chemother.42(3), 550–554 (1998).
   PubMedGoogle Scholar
• Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother.50(6), 1011–1015 (2002).
   PubMed Web of Science ®Google Scholar
• Demkow U, Radomska D, Chorostowska-Wynimko J, Skopinska-Rozewska E. The influence of rifampicin on selected parameters of immunologic response. Pneumonol. Alergol. Pol.66(1–2), 45–53 (1998).
   PubMedGoogle Scholar
• Littlewood-Evans AJ, Hattenberger M, Zak O, O’Reilly T. Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. J. Antimicrob. Chemother.39, 493–498 (1997).
   PubMedGoogle Scholar
• Barracchini A, Franceschini N, Di Giulio A et al. Metalloproteinase inhibition: therapeutic application in rheumatic diseases. Clin. Ter.150(4), 295–299 (1999).
   PubMedGoogle Scholar
• Feldman DL, Sawyer WK, Jeune MR et al. CGP 43371 paradoxically inhibits development of rabbit atherosclerotic lesions while inducing extra-arterial foam cell formation. Atherosclerosis154(2), 317–328 (2001).
   PubMedGoogle Scholar
• Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multi-drug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampicin. Drug Metab. Dispos.30, 20–26 (2002).
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal mdR1 by rifampin. J. Biol. Chem.276, 14581–14587 (2001).
   PubMed Web of Science ®Google Scholar
• Granzotto M, Drigo I, Candussio L et al. Rifampicin and verapamil induce the expression of P-glycoprotein in vivo in Ehrlich ascites tumor cells. Cancer Lett.205(1), 107–115 (2004).
   PubMedGoogle Scholar
• Magnarin M, Morelli M, Rosati A et al. Induction of proteins involved in multi-drug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur. J. Pharmacol.483(1), 19–28 (2004).
   PubMed Web of Science ®Google Scholar
• Fromm MF, Kauffmann HM, Fritz P et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Amer. J. Pathol.157(5), 1575–1580 (2000).
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet.42(9), 819–850 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas GA, Swift GL, Green JT et al. Controlled trial of antituberculous chemotherapy in Crohn’s disease: a 5-year follow-up study. Gut42, 497–500 (1998).
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob. Agents Chemother.36, 2843–2846 (1992).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn’s disease. N. Engl. J. Med.337, 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340, 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum. Dis. Clin. North Am.30(2), 257–270 (2004).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum.50(2), 372–379 (2004).
   PubMed Web of Science ®Google Scholar
• Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin. Pharmacol. Ther.74(6), 591–592, (2003).
   PubMedGoogle Scholar
• Ashitani J, Yanagi S, Arimura Y, Sano A, Mukae H. Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. Respiration70(5), 541–543 (2003).
   PubMed Web of Science ®Google Scholar
• Le Gars L, Collon T, Picard O, Kaplan G, Berenbaum F. Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. J. Rheumatol.26, 1201–1202 (1999).
   PubMedGoogle Scholar
• van Denderen JC, Mensen EA, Vints AM. Arthritis caused by use of rifabutine in Mycobacterium avium infection. Ned. Tijdschr. Geneeskd.18(141), 2028–2030 (1997).
   Google Scholar
• Khan MA, Singh J, Dhillon B. Rifabutin-induced uveitis with inflammatory vitreous infiltrate. Eye14(Pt 3A), 344–346 (2000).
   PubMedGoogle Scholar
• Jaffuel D, Demoly P, Gougat C, Mautino G, Bousquet J, Mathieu M. Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells. Mol. Pharmacol.55(5), 841–846 (1999).
   PubMedGoogle Scholar
• Ray DW, Lovering AM, Davis JRE, White A. Rifampicin; a glucocorticoid receptor ligand? Nature Med.4(10), 1090 (1998).
   PubMedGoogle Scholar
• Calleja C, Pascussi JM, Mani JC, Maurel P, Vlarem MJ. Rifampicin; a glucocorticoid receptor ligand? Reply. Nature Med.4(10), 1090 (1998).
   PubMedGoogle Scholar
• Blanchard JS. The Ying and Yang of rifampicin. Nature Med.4(1), 14–15 (1998).
   PubMedGoogle Scholar
• Holland SM. Cytokine therapy of mycobacterial infections. Adv. Intern. Med.45, 431–452 (2000).
   PubMedGoogle Scholar
• Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract. Res. Clin. Rheumatol.18(1), 31–45 (2004).
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor κB: an emerging theme in anti-inflammatory therapies. Mol. Intervent.2(1), 22–35 (2002).
   PubMedGoogle Scholar
• Dinarello CA. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol.20(Suppl. 5), S1–13 (2002).
   PubMed Web of Science ®Google Scholar
• Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. NY Acad. Sci.1024, 124–137 (2004).
   PubMed Web of Science ®Google Scholar
• Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nature Rev. Drug. Discov.3(5), 401–416 (2004).
   PubMed Web of Science ®Google Scholar
• Di Virgilio F. New pathways for reactive oxygen species generation in inflammation and potential novel pharmacological targets. Curr. Pharm. Des.10(14), 1647–1652 (2004).
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S, Thiemermann C, Salvemini D. Potential therapeutic effect of anti-oxidant therapy in shock and inflammation. Curr. Med. Chem.11(9), 1147–1162 (2004).
   Google Scholar